Christopherk Murray News Today

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have given a buy recommendation and […]

Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, nine have issued a buy recommendation and one has […]

Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 4,540,000 shares, a growth of 6.8% from the April 15th total of 4,250,000 shares. Based on an average trading volume of 830,500 shares, the days-to-cover ratio […]

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […]

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price target lifted by Piper Sandler from $78.00 to $104.00 in a research note published on Friday, Benzinga reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock. Several other research firms also recently commented on BPMC. Wedbush reiterated an outperform rating and issued […]

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $125.00 to $135.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential […]

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […]

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lifted by investment analysts at Barclays from $70.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside […]

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lifted by investment analysts at Barclays from $70.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside […]